Effects of antidepressant treatment on neuroactive steroids in major depression

被引:391
作者
Romeo, E
Ströhle, A
Spalletta, G
di Michele, F
Hermann, B
Holsboer, F
Pasini, A
Rupprecht, R
机构
[1] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy
[2] Univ Roma Tor Vergata, Dept Psychiat, Rome, Italy
[3] Max Planck Inst Psychiat, D-80804 Munich, Germany
关键词
D O I
10.1176/ajp.155.7.910
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: There is evidence from animal studies that fluoxetine may enhance the concentrations of neuroactive steroids. Therefore, the authors investigated whether clinically effective treatment with antidepressants may alter the concentrations of neuroactive steroids in patients suffering from a major depressive episode. Method: In the first study, eight drug-native outpatients with major depression were studied during treatment with fluoxetine. In a complementary study, 11 inpatients with major depression were studied during a severe depressive episode and after recovery following treatment with different antidepressants. Plasma samples were quantified for neuroactive steroids by means of a highly sensitive and specific combined gas chromatography/mass spectrometry analysis. Results: During depression, there tons a significant ;decrease in 3 alpha, 5 alpha-tetrahydroprogesterone (3 alpha, 5 alpha-THP) and 3 alpha, 5 beta-THP concentrations, both of which are positive modulators of the gamma-aminobutyric acid(A) receptor, and a concomitant increase in 3 beta, 5 alpha-THP levels. This dysequilibrium of neuroactive steroids could be corrected by treatment with different antidepressants. Conclusions: These results provide the first clinical evidence of a possible role of neuroactive steroids in successful antidepressant therapy.
引用
收藏
页码:910 / 913
页数:4
相关论文
共 18 条
[11]   THE NEUROSTEROID TETRAHYDROPROGESTERONE COUNTERACTS CORTICOTROPIN-RELEASING HORMONE-INDUCED ANXIETY AND ALTERS THE RELEASE AND GENE-EXPRESSION OF CORTICOTROPIN-RELEASING HORMONE IN THE RAT HYPOTHALAMUS [J].
PATCHEV, VK ;
SHOAIB, M ;
HOLSBOER, F ;
ALMEIDA, OFX .
NEUROSCIENCE, 1994, 62 (01) :265-271
[12]   NEUROACTIVE STEROIDS [J].
PAUL, SM ;
PURDY, RH .
FASEB JOURNAL, 1992, 6 (06) :2311-2322
[13]   5-BETA-PREGNAN-3-BETA-OL-20-ONE, A SPECIFIC ANTAGONIST AT THE NEUROSTEROID SITE OF THE GABA-A RECEPTOR-COMPLEX [J].
PRINCE, RJ ;
SIMMONDS, MA .
NEUROSCIENCE LETTERS, 1992, 135 (02) :273-275
[14]  
ROMEO E, 1994, J PHARMACOL EXP THER, V270, P89
[15]   The neuropsychopharmacological potential of neuroactive steroids [J].
Rupprecht, R .
JOURNAL OF PSYCHIATRIC RESEARCH, 1997, 31 (03) :297-314
[16]   PROGESTERONE RECEPTOR-MEDIATED EFFECTS OF NEUROACTIVE STEROIDS [J].
RUPPRECHT, R ;
REUL, JMHM ;
TRAPP, T ;
VANSTEENSEL, B ;
WETZEL, C ;
DAMM, K ;
ZIEGLGANSBERGER, W ;
HOLSBOER, F .
NEURON, 1993, 11 (03) :523-530
[17]   Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography [J].
Uzunov, DP ;
Cooper, TB ;
Costa, E ;
Guidotti, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (22) :12599-12604
[18]   Relationship between symptom severity and steroid variation in women with premenstrual syndrome: Study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one [J].
Wang, MD ;
Seippel, L ;
Purdy, RH ;
Backstrom, T .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (03) :1076-1082